Stella Pharma Corporation
Progress of Research and Development toward expanding BNCT indications in Deep-seated Cancer areas through collaboration with Fujita Medical University
Reporting progress of R&D aimed at expanding BNCT indications into deep-seated cancer areas in collaboration with Fujita Medical University and others. Conducted exploratory research using 18F-FBPA PET, laying the groundwork for expanding indications to deep-seated tumors. Positioned as a pillar of the long-term growth strategy including transition to implementation phase and overseas expansion from 2026 onward.
Key Figures
- R&D Memorandum Signed: December 2024
- BNCT treatment system deployment contract: January 2026
- Number of target diseases: 50 cases (for 18F-FBPA PET exploratory research in deep-seated cancers)
AI要約
Background and objectives of R&D
StarlaPharma is pushing development targeting deep-seated cancers in collaboration with Fujita Medical University and other institutions to broaden BNCT treatments to more cancer types. BNCT combines boron agents with neutron irradiation, where tumor uptake and irradiation suitability are key to treatment success, making it essential to address technical challenges such as improving neutron reach for deeper regions.
Current projects and future outlook
Under the collaboration with Fujita Medical University, Atransen Pharma, Sumitomo Heavy Industries, and Fujita, started with a memorandum signed in December 2024 to advance BNCT research for deep-seated tumors. An deployment contract for BNCT treatment system and dose calculation program was signed in January 2026, moving toward concrete implementation. 18F-FBPA PET exploratory research will accumulate insights on boron agent behavior in deep-seated cancers to consider future indication expansion possibilities.
StarlaPharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
